FreeTheAI

Vivos Therapeutics Acquires 11% Stake in SOD Sciences in $12 Million All-Stock Deal

MixedMedium impact
VVOS$0.1329 −0.82%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has signed a definitive agreement to purchase an 11% equity stake in SOD Sciences, Inc. alongside a 50% co-ownership interest in SOD's proprietary pseudohypoxia early-warning test. In exchange, Vivos will issue 12,000 shares of newly created Series C Convertible Preferred Stock with a total stated value of $12 million, requiring no cash payout at closing.

The deal is designed to strengthen the company's financial standing by increasing reported stockholders' equity. Vivos expects the added equity to support its efforts to regain compliance with Nasdaq listing requirements. Additionally, the agreement creates avenues for commercial research and marketing alliances, including prospective opportunities with Cleveland Clinic Weston and American Health Associates.

Closing is expected around October 15, 2026, subject to customary closing conditions such as auditor concurrence and Nasdaq notification. Investors will be monitoring whether the transaction successfully satisfies Nasdaq rules and if Vivos can secure the required shareholder approval to convert preferred shares into common stock above the current exchange cap.

Key points

  • Vivos Therapeutics, Inc. (NASDAQ:VVOS) agreed to acquire an 11% equity stake in SOD Sciences, Inc. and 50% co-ownership of its pseudohypoxia test.
  • The $12 million transaction is paid entirely in newly created Series C Convertible Preferred Stock with no cash involved.
  • Vivos expects the deal to boost stockholders' equity and aid in regaining compliance with Nasdaq continued listing standards.
  • The partnership opens prospective commercial and research relationships with Cleveland Clinic Weston and American Health Associates.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did Vivos Therapeutics acquire from SOD Sciences?

Vivos Therapeutics acquired an 11% equity stake in SOD Sciences and a 50% undivided co-ownership interest in its proprietary pseudohypoxia early-warning test.

How is Vivos Therapeutics paying for the SOD Sciences deal?

Vivos is issuing 12,000 shares of Series C Convertible Preferred Stock with an aggregate value of $12 million. No cash is payable at closing.

Why is Vivos Therapeutics entering this transaction?

Vivos expects the preferred stock classification to increase reported stockholders' equity, helping the company attempt to regain compliance with Nasdaq listing rules.